Eisai eritoran Phase II sepsis data

Eisai (Tokyo:4523) said 105 mg of its eritoran ( E5564) reduced all-cause mortality by 6.4% compared with placebo in a North American Phase II trial in 293 patients with severe sepsis (p=0.34). The pr...